Figure 4. Assessment of tumor-specific immunity.
Splenocytes were collected from mice treated with PBS, RdB, RdB/IL12, RdB/DCN, or RdB/IL12/DCN at 6 days after final treatment and co-incubated with pre-irradiated 4T1 cells for 1 day. Assays were IFN-γ ELISPOT. (A) Spot-forming cell response. Images are representatives of results from three independent experiments. (B) Number of spots for 2.5 × 105 splenocytes. Values are mean spot number ± SD for triplicates representative of three independent experiments. *P < 0.05, **P < 0.01, or ***P < 0.001. (C, D) Quantification of IFN-γ and TNF-α from tumor-specific immune cells. Splenocytes were co-cultured with pre-irradiated 4T1 cells for 2 days. IFN-γ and TNF-α were evaluated in co-cultured supernatants by cytometric bead array (CBA) mouse inflammation kits. Data points are mean ± SD of triplicates representative of three independent experiments. ***P < 0.001.